Long/short equity, biotech, healthcare, small-cap

Why NuVasive Is A Good Long-Term Bet

NuVasive (NUVA) recently announced its third-quarter earnings, and despite the OIG, subpoena related to Medicare/Medicaid false claims, it was able to surpass Wall Street's earnings expectations. Solid execution, the end of physician owned devices or PODs, and a maturing spine market allowed NuVasive to beat analysts' third quarter revenue expectations. Furthermore, the accelerating U.S. implant market and sales force stability are boosting NuVasive's stock price to gain further upside.

I expect the combination of NuVasive's lateral offering, robust development pipeline, physician/patient advocacy programs, and strong recent history of market share gains to facilitate the company to maintain its market-leading position and above-market growth rates. Furthermore, the fraud-alert issued by the OIG related to the business practices of PODs...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details